Cagrilintide + Semaglutide
Fixed-dose combination of an amylin analogue and a GLP-1 receptor agonist studied for obesity and metabolic disease, with region- and product-specific regulatory status.
This page is for general educational and informational purposes only. It is not medical advice and does not replace professional medical judgment. Always consult a qualified clinician before starting, stopping, or changing any medication or protocol.
Overview
This entry describes a fixed-dose combination of cagrilintide, an amylin analogue, and semaglutide, a GLP-1 receptor agonist. The combination has been investigated for obesity and related metabolic conditions.
Regulatory status, approved indications, and product names vary by region and over time.
Mechanism of action
Cagrilintide mimics aspects of amylin signaling, influencing satiety and gastric emptying, while semaglutide activates GLP-1 receptors to affect insulin secretion, appetite, and GI motility.
Together, these pathways may produce additive or synergistic effects on appetite regulation and metabolic parameters.
Indications and use context
Clinical programs have focused on weight management and metabolic risk reduction. Any approved indications are product- and jurisdiction-specific.
Catalog listing of this combination reflects interest in multi-pathway metabolic modulation and does not imply endorsement of off-label regimens.
Safety and side effects
Safety considerations for cagrilintide + semaglutide combine those of the individual agents and the additive effects on gastrointestinal and metabolic pathways.
Commonly described adverse effects in this class include nausea, vomiting, diarrhea or constipation, and potential impacts on gallbladder and pancreatic physiology. Product labeling and up-to-date guidelines remain the primary references for risk information.
Pharmacology and dosing considerations
CagriSema combines two long-acting agents. Investigational protocols mirror the weekly titration steps of semaglutide alone but with careful monitoring for nausea.
Route: Subcutaneous injection.
Protocol structure and dosage:- Frequency: Once weekly.
- Titration: Starting at 0.25 mg/0.25 mg (or similar low ratio) and increasing every 4 weeks.
- Max Dose: Investigational doses reach 2.4 mg/2.4 mg weekly.
This information is based on ongoing Phase 3 clinical trials (REDEFINE).
Formulations and combinations
Structurally, this catalog entry groups cagrilintide and semaglutide into a single SKU to mirror combination products under investigation or in development.
Listing of a combination product does not recommend stacking additional weight-loss agents on top of it.
Research and evidence snapshot
Trials of cagrilintide + semaglutide have evaluated weight loss, metabolic markers, and safety outcomes relative to single agents or placebo.
As with all emerging obesity therapies, interpretation of results requires attention to study design, comparator arms, and long-term follow-up.
Frequently asked questions
Future FAQs may compare this combination conceptually with single-agent GLP-1 receptor agonists or other multi-agonists, and discuss how clinicians weigh potential incremental benefits against complexity and risk. Answers will remain educational and non-prescriptive.
Comments
Loading comments...
Get the Standard Protocols.
Join 12,000+ researchers. Receive weekly breakdowns of new compounds, safety data updates, and source verification reports.